CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Nitrostat 0.4Mg Sublingual Tabletdrug
Likely dose
Nitrostat 0.4Mg Sublingual Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03305848
NCT03305848Phase 4Completed
CompareCT.gov

Efficacy and Safety of Oral Nitroglycerin on Esophageal Food Impaction

HealthPartners Institute·interventional·Posted Oct 10, 2017·Updated Feb 8, 2023

In Brief

A Phase 4 clinical trial evaluating Nitrostat 0.4Mg Sublingual Tablet for Esophageal Food Bolus Obstruction. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study is designed to obtain data on the safety and efficacy of oral nitroglycerin solution for the treatment of esophageal food impaction in patients presenting to the Emergency Department with presumed esophageal food impaction. The main hypothesis is to determine the success rate of oral nitroglycerin solution in relieving the food impaction by assessing the resolution of symptoms and the ability of the patient to swallow.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Food Bolus Obstruction
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 10, 2017
Enrollment StartAug 25, 2017
Primary CompletionApr 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.7 years ago

Interventions

Nitrostat 0.4Mg Sublingual Tabletdrug

Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure \> 100 mmHg.